Back
Verona Pharma PLC 10K Form
Sell
48
VRNA
Verona Pharma PLC
Last Price:
$66.64
Seasonality Move:
-2.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-02 | 10Q | VRNA/Verona Pharma PLC Quarterly |
2023-08-03 | 10Q | VRNA/Verona Pharma PLC Quarterly |
2023-05-09 | 10Q | VRNA/Verona Pharma PLC Quarterly |
2022-11-09 | 10Q | VRNA/Verona Pharma PLC Quarterly |
2022-08-09 | 10Q | VRNA/Verona Pharma PLC Quarterly |
2022-05-03 | 10Q | VRNA/Verona Pharma PLC Quarterly |
Receive VRNA News And Ratings
See the #1 stock for the next 7 days that we like better than VRNA
VRNA Financial Statistics
Sales & Book Value
Annual Sales: | $42.3M |
---|---|
Cash Flow: | $-29.4M |
Price / Cash Flow: | 0 |
Annual Sales: | $2.42 |
Price / Book: | 25.5 |
Profitability
EPS (TTM): | -2.16000 |
---|---|
Net Income (TTM): | $-173.4M |
Gross Margin: | $39.7M |
Return on Equity: | -88.7% |
Return on Assets: | -45.92% |
Verona Pharma PLC Earnings Forecast
Key Verona Pharma PLC Financial Ratios
-
The Gross Profit Margin over the past 14 years for VRNA is 93.89%.
-
The Selling, General & Administrative Expenses for VRNA have been equal to 354.19% of Gross Profit Margin.
-
The Research & Development expenses have been 105.43% of Revenue.
-
The Net Earning history of VRNA is -410.18% of Total Revenues.
-
Per Share Earnings over the last 20 years have been positive in 9 years.
Verona Pharma PLC Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | VRNA |
CUSIP: | 925050 |
Website: | veronapharma.com |
Debt
Debt-to-Equity Ratio: | 0.59 |
---|---|
Current Ratio: | 10.63 |
Quick Ratio: | 10.24 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 288.89 |
VRNA Technical Analysis vs Fundamental Analysis
Sell
48
Verona Pharma PLC (VRNA)
is a Sell
Is Verona Pharma PLC a Buy or a Sell?
-
Verona Pharma PLC stock is rated a SellThe current Verona Pharma PLC [VRNA] share price is $61.39. The Score for VRNA is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.